SUPN - Supernus Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
408,243
408,897
302,238
215,003
Cost of Revenue
16,735
15,356
15,215
11,986
Gross Profit
391,508
393,541
287,023
203,017
Operating Expenses
Research Development
79,148
89,209
49,577
42,791
Selling General and Administrative
164,750
159,888
137,905
106,010
Total Operating Expenses
243,898
249,097
187,482
148,801
Operating Income or Loss
147,610
144,444
99,541
54,216
Interest Expense
22,437
18,111
1,568
5,091
Total Other Income/Expenses Net
-
-
-219
-238
Income Before Tax
145,342
140,176
100,618
50,369
Income Tax Expense
39,522
29,183
43,334
-40,852
Income from Continuing Operations
105,820
110,993
57,284
91,221
Net Income
105,820
110,993
57,284
91,221
Net Income available to common shareholders
105,820
110,993
57,284
91,221
Reported EPS
Basic
-
2.13
1.13
1.84
Diluted
-
2.05
1.08
1.76
Weighted average shares outstanding
Basic
-
51,990
50,757
49,472
Diluted
-
54,099
53,301
51,709
EBITDA
-
158,287
102,186
55,460